The antifibrillatory properties of short-term intravenous (10 mg/kg/hr) and long-term (10 mg/kg/day for 24 days) oral amiodarone administration were examined in a conscious canine preparation of sudden coronary death. In this preparation, ventricular fibrillation was produced by electrically induced left circumflex intimal injury and thrombosis in the presence of previous anterior myocardial infarction. On day 4 after anterior myocardial infarction animals were assigned to receive short-term intravenous or long-term oral amiodarone treatment. Animals within each group were randomly assigned to control or drug treatment. Neither short-term intravenous nor long-term oral amiodarone treatment prevented the development of ST segment changes or premature ventricular beats, but both short-term intravenous amiodarone and long-term oral amiodarone administration significantly reduced the incidence of ventricular fibrillation (short-term intravenous amiodarone [n = 10], incidence of 60% vs control [n = 10] incidence of 100%, p < .05; long-term oral amiodarone [n = 10], incidence of 20% vs control [n = 11] incidence of 91%, p < .002). Both short-term intravenous and long-term oral amiodarone administration produced increases in the PR and ratecorrected QT intervals. However, prolongation of the corrected QT interval in the group receiving long-term oral amiodarone (61 + 18 msec) was greater than in the group receiving short-term intravenous drug (31 ± 11 msec, p < .05). This discrepancy between effects of long-term oral and short-term intravenous amiodarone could not be based on differences in plasma (1.9 0.2 vs 2.7 + 0.5 gg/ml, respectively) or right ventricular myocardial concentrations (13 + 2 vs 24 + 4 ,g/g, respectively). These data suggest that while both long-term oral amiodarone and short-term intravenous amiodarone prevent ventricular fibrillation in the conscious dog subjected to acute myocardial ischemia in the presence of previous anterior myocardial infarction, long-term oral amiodarone may have an additional electrophysiologic action and therefore greater efficacy. Circulation 68, No. 4, 857-864, 1983. AMIODARONE HYDROCHLORIDE is a benzofuran derivative originally developed as an antianginal drug. It is both a coronary vasodilator and a vasodilator of the peripheral vasculature.'-3 Amiodarone also exerts noncompetitive blockade of the actions of 38adrenergic agonists and reduces the inotropic and chronotropic response of other inotropic drugs such as glucagon.
duced, which may be in part due to development of an atropine-resistant bradycardia.I These properties may in part be responsible for the antianginal effects of the drug and may also be factors involved in the ability of the drug to reduce the extent of irreversible injury associated with experimental myocardial infarction. 4 Although amiodarone lacks local anesthetic properties,5 the drug is effective in the short-term treatment and long-term prophylaxis of supraventricular tachycardias in man. 6' 7 This action has been attributed to the ability of the drug to uniformly prolong action potential duration5 and increase the effective refractory period of atrial and atrioventricular nodal tissue.7 Recent experimental data have also suggested that amiodarone may be effective in the long-term prophylaxis of ventricular tachyarrhythmias in patients at high risk for sudden coronary death.8'-1 The ability of amiodarone, or any other drug, to prevent ventricular tachycardia and ventricular fibrillation resulting from ischemic injury may be a critical test for evaluating the potential efficacy of drug therapy in reducing mortality from lethal ventricular arrhythmias. In this report we evaluate the ability of short-term intravenous and long-term oral amiodarone to prevent ventricular fibrillation in the conscious dog subjected to left circumflex intimal injury and thrombosis in the presence of previous anterior myocardial infarction. This model may provide crucial information concerning the potential of amiodarone to prevent the spontaneous development of ventricular fibrillation.
Methods
Animal preparation. Male mongrel dogs were anesthetized with 30 mg/kg iv sodium pentobarbital. By an aseptic technique a left thoracotomy was performed in the fourth intercostal space and the heart was suspended in a pericardial cradle. The left anterior descending coronary artery was isolated free from surrounding myocardium at the tip of the left atrial appendage. A critical stenosis was placed around the artery with suture and a 19-gauge hypodermic needle. The stenosis reduced the hyperemic response to a 10 sec occlusion of the left anterior descending coronary artery without reducing resting coronary blood flow. Coronary blood flow was measured with an electromagnetic flow probe. The artery was occluded with a snare formed by passing a loop of silicone rubber tubing through a flared section of polyethylene tubing. After 2 hr flow was restored through the stenosed artery.
The left circumflex coronary artery was isolated free from surrounding myocardium approximately 5 mm from the origin. The bared 3 mm tip of an insulated silver wire was inserted into the vessel lumen and secured to the surface of the heart. Silver disc electrodes were implanted subcutaneously to monitor a lead II electrocardiogram and the chest was closed in layers. Ampicillin (20 mg/kg) was administered intramuscularly and the animals were allowed to recover from surgery. Antibiotic therapy was continued until day 4 after myocardial infarction.
Drug administrationshort-term amiodarone. On day 4 after anterior myocardial infarction, animals were assigned randomly to an amiodarone or saline treatment group. Amiodarone-treated animals received 10 mg/kg/hr of intravenous drug in a 20% ethanol:80% saline mixture (40 ml total). Arterial blood pressure was measured from a catheter previously placed into the left common carotid artery and a lead I1 electrocardiogram was recorded from subcutaneous electrodes. After 1 hr of drug administration into the left external jugular vein, an anodal current of 150 gA was applied to the left circumflex intimal surface, as described below. A venous blood sample (3 ml) was obtained in a syringe containing 300 units sodium heparin at the onset of ST segment change. In animals dying from development of ventricular fibrillation, cardiac tissue samples from atrium and right ventricle were obtained. Drug administration was discontinued 1 hr after development of ST segment changes in surviving animals.
Drug administrationlong-term amiodarone. On day 4 after anterior myocardial infarction animals were assigned randomly to a control or amiodarone treatment group. Amiodarone-treated animals received 10 mg/kg drug orally each day for 24 days and control animals received no treatment. A lead II electrocardiogram was monitored in the conscious dog before 858 surgery and on days 4, 7, 14, 21, and 28 after myocardial infarction. Venous blood samples were obtained on days 4, 7, 14, 21, and 28 after myocardial infarction in amiodarone-treated animals.
Initiation of current flow to the intimal surface of the left circumflex coronary artery. On day 4 or day 28 after myocardial infarction an anodal current of 150 /jA was applied to the intimal surface of the left circumflex coronary artery for 12 hr with a 9 V battery and potentiometer. A lead II electrocardiogram was transmitted via radiotelemetry and recorded on a Grass model 7 polygraph. The telemetry device and battery pack were contained within a pouch in a nylon vest that allowed the experiments to be performed in conscious ambulatory dogs.
After development of ventricular fibrillation or after an overdose of sodium pentobarbital at 24 hr after initiation of left circumflex intimal stimulation, the dog's hearts were removed and sectioned into 5 mm thick sections parallel to the atrioventricular groove. Atria and right ventricle were removed from amiodarone-treated hearts for analysis of tissue amiodarone concentration. The sections were then placed into 0.5% triphenyltetrazolium hydrochloride in 0.O1M potassium phosphate, pH 7.4. Triphenyttetrazolium is a histochemical reagent that forms a brick-red precipitate in the presence of intracellular dehydrogenases and thereby demarcates viable myocardium. The proximal left circumflex coronary artery was removed and the thrombus mass was determined.
Determination of amiodarone in plasma and myocardium. Plasma and myocardial concentrations were determined by high-performance liquid chromatography (Varian model 5000). The mobile phase was 14% acetonitrite, 60% methanol, 0.01 mM sodium octylsulfonate, and 26% distilled water delivered at 1.5 ml/min with a C-18 stationary phase column (Waters). The column was maintained at a temperature of 44°C. Detection was with ultraviolet absorption at 245 nm.
To 1 ml plasma or tissue homogenate 1 ml phosphate buffer, 0.67M, pH 5.4, 1 ,gg L-8040 (internal standard), and 2 ml Nheptane:isobutanol (95:5) was added. After 10 min of mixing, the organic layer was removed and evaporated under nitrogen.
The residue was reconstituted in 100 ,ul ethanol and an aliquot was injected for analysis. Tissue homogenates were prepared with a Tekmar Tissuemizer (Tekmar Instruments, Cincinnati) and the supernatant was analyzed. Statistics. Student's t test for unpaired data was used to analyze differences between groups. Survival data were analyzed by Fisher's exact test. The data are expressed as mean + SEM.
Histologic examination. Transmural sections of anterior and posterior myocardium were removed and placed in 10% formalin for examination by standard techniques of light microscopy.
Results
Short-term studiesinitiation of left circumflex coronary artery intimal injury on day 4 after anterior myocardial infarction. Both control (n = 10) and amiodaronetreated animals (n = 10) were studied on day 4 after myocardial infarction. A continuous intravenous infusion of 10 mg/kg/hr amiodarone was given from 1 hr before intimal stimulation up to 1 hr after ST segment changes first appeared. The administration of amiodarone failed to prevent development of ST changes indicative of acute ischemia and failed to prevent or delay development of premature ventricular beats. Control animals rapidly developed ventricular tachy- cardia and ventricular fibrillation. All 10 control animals developed ventricular fibrillation while four of 10 animals receiving short-term intravenous amiodarone survived to 24 hr (p < .05; figure 1, table 1). Shortterm drug administration did significantly reduce the sinus tachycardia accompanying development of acute myocardial ischemia (table 1) .
Mean plasma amiodarone concentration at the time of ST segment changes was 2.7 ± 0.5 ,ug/ml and atrial muscle and right ventricular concentrations were 26.2 ± 6.4 and 24.3 ± 3.7 ug/g, respectively, at autopsy. No desethylamiodarone was detected.
No difference in the mass of anterior infarction was observed between control (18 ± 1% of left ventricle) and short-term amiodarone treatment (19 ± 2% of left ventricle) groups. Only the four drug-treated animals surviving to 24 hr developed posterior wall (left circumflex distribution) infarction (21 ± 3% of left ventricle). Thrombus mass was 9 ± 2 mg for control and 14 ± 6 mg for amiodarone-treated animals (table l) .
Long-term studies. Anterior myocardial infarction was produced in 28 animals by a temporary 90 min occlusion of the left anterior descending coronary artery, and the tip of an insulated silver wire was placed in the lumen of the left circumflex coronary artery. Twenty-four animals survived to day 4 after myocardial infarction and were assigned to the control or longterm amiodarone treatment group.
Initiation of left circumflex coronary artery intimal injurycontrol group on day 28 tion of the left anterior descending coronary artery were evident in all animals and constituted 12 + 3% of the total left ventricular mass. Histologic examination of the anterior wall revealed the presence of granulation tissue and connective tissue within the distribution of the left anterior descending coronary artery. No evidence of posterior wall infarction was observed histochemically or with light microscopy in control animals developing ventricular fibrillation, but it was present in one animal surviving to 24 hr (14% of left ventricular mass).
Initiation of left circumflex coronary artery intimal injurylong-term oral amiodarone group. Ten animals received oral amiodarone (10 mg/kg) daily from day 4 to day 28 after myocardial infarction. Administration of amiodarone resulted in a time-dependent increase in plasma amiodarone concentrations and in the corrected QT interval ( . Survival curves for conscious canine preparation of sudden coronary death after long-term amiodarone treatment. Cumulative survival curves for control and amiodarone-treated animals are shown. Amiodarone-treated animals received 10 mg/kg/day oral drug for 24 days before intimal stimulation of the left circumflex coronary artery on day 28 after anterior myocardial infarction. Survival was significantly increased (p < .002) by amiodarone treatment.
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On day 28 after myocardial infarction, a current of 150 ,A was applied to the intimal surfaces of the left circumflex coronary arteries of the conscious ambulatory dogs, resulting in damage to the intimal surface. ST segment changes became evident and were accompanied by premature ventricular beats (table 3) . Ventricular tachycardia was present in all 10 animals, but eight of 10 animals did not develop ventricular fibrillation and survived to 24 hr (p < .002 vs control). An example of a lead II electrocardiogram from an amiodarone-treated animal is shown in figure 4 and a cumulative survival curve is shown in figure 2 . The mean right ventricular myocardial concentration of amiodarone at day 28 was 13.2 + 2.0 ,ug/ml and the atrial muscle concentration was 42 ± 7 ,tg/ml. This represented a sevenfold uptake in right ventricular myocardium and a 22-fold uptake in atrial tissue. The atrial desethylamiodarone concentration was 32 ± 8 ,ug/g with a right ventricular concentration of 54 ± 17 pug/g, representing a 20-fold (+ 9) and 33-fold (± 11) uptake, respectively.
The thrombus mass in amiodarone-treated animals was 27 ± 5 mg and was significantly greater than that in control animals (11 + 2 mg, p < .05). No difference in infarct mass within the left anterior descending coronary artery distribution was observed between the control and the amiodarone-treated group (12 + 3% vs 11 + 3% of total left ventricular mass). Myocardial infarction was present within the distribution of the left circumflex coronary artery in all eight amiodaronetreated animals surviving to 24 hr and represented 16 + 2% of total left ventricular mass (table 2) .
Discussion
Clinical electrophysiologic studies have identified differences in the responses to short-term intravenous amiodarone and long-term oral amiodarone therapy. The effects of long-term oral amiodarone on right ventricular effective refractory periods are much greater than those observed after short-term intravenous amiodarone."1, 12 This was seen despite the immediate effects observed on atrioventricular nodal refractoriness and conduction after intravenous amiodarone." Although some investigators have observed significant antiarrhythmic actions after short-term intravenous administration,'3' 14 other investigators have failed to observe substantial drug action until after several days of administration. 15 In the present study we observed antifibrillatory actions both after short-term intravenous and long-term oral administration. However, the effect of amiodarone on the QT segment was more profound after long-term oral administration and efficacy of the drug with respect to the prevention of ventricular fibrillation appeared to be greater after this dosage. Amiodarone, 10 mg/kg/day orally for 24 days or 10 mg/kg/hr iv, significantly reduced the incidence of ventricular fibrillation in the conscious dog subjected to electrically induced left circumflex coronary artery intimal injury in the presence of previous anterior myocardial infarction. The mechanism responsible for this protective action is not well defined. In view of the many varied pharmacologic actions of amiodarone, a number of potential mechanisms can be suggested. Amiodarone administration (20 mg/kg/day for 42 days) produces a uniform prolongation of repolarization and increases action potential duration in the atrial and ventricular muscle of rabbits.5 This action is observed without alteration of the resting membrane potential or action potential amplitude. Only a small depression of phase 0 upstroke velocity is observed.5 Similar electrophysiologic changes are also observed after short-term intravenous'6 or long-term oral amiodarone. 'o.l7 Atrial and right ventricular refractory periods are significantly prolonged by administration of certain drugs in man. Although the short-term changes in myocardial conduction and refractoriness can be effective in depressing the conduction of rapid atrial rates to the ventricle through the atrioventricular node or through atrioventricular bypass pathways,6 7 16 it is difficult to ascribe the suppression of ventricular tachyarrhythmias after short-term amiodarone to the prolongation of ventricular repolarization and an increase in ventricular effective refractory periods since no change in these parameters is usually observed after short-term amiodarone. 17 The ability of amiodarone to suppress ventricular ectopy and recurrent ventricular tachyarrhythmias develops slowly, often becoming evident only after 7 to 10 days of oral therapy and reaching a maximum after 4 to 5 weeks of therapy.' '7 '8 A parallel change is also observed with prolongation of the QT interval.6 Many investigators have attributed the delay in the onset of the antiarrhythmic action and the QT segment prolongation to a slow accumulation of amiodarone in plasma with long-term oral therapy.6'-0, 7 The slow accumulation of amiodarone in plasma may be a result of either extensive uptake and storage of the drug in adipose tissue'9 or a long plasma half-life with an attendant slow attainment of steady-state plasma drug concentrations.20 21 In man, the plasma half-life at steady state is in excess of 12 days20 and could account for the delayed onset of the therapeutic effect. In the present study, amiodarone accumulated slowly in plasma during long-term oral therapy and reached a plateau only after 21 days of therapy. Prolongation of the PR interval and rate-corrected QT intervals followed in a parallel fashion, suggesting a correlation between plasma drug concentrations and electrophysiologic effects. Nevertheless, short-term intravenous administration of amiodarone to equivalent plasma and cardiac tissue concentrations did not produce equivalent prolongation of the QT interval and was not as effective in preventing the development of ventricular fibrillation. There is considerable information to suggest that the slow development of metabolic alterations in thyroid hormone activity may play a role in the efficacy of long-term oral amiodarone.22 23 Long-term oral amiodarone increases plasma concentrations of reverse triiodothyronine (T3) and thyroxine.23 The changes in thyroid hormone disposition parallel the onset and magnitude of negative chronotropy, QT segment prolongation, and suppression of premature ventricular contractions. 23 Experimental evidence also shows that prolongation of repolarization and increased action potential duration in rabbit atrial and ventricular muscle by amiodarone is suppressed by concomitant administration of exogenous thyroxine.' Moreover, thyroidectomy produces a uniform delay in repolarization of atrial and ventricular muscle potentials in rabbit myocardium, an action virtually indistinguishable from that of amiodarone.24 Several authors have speculated that a specific inhibition of the conversion of thyroxine to T3 occurs in cardiac muscle, thereby decreasing the production of the active metabolite T3 in cardiac muscle and decreasing the breakdown of thyroxine in plasma.5 24 The decreased metabolism of thyroxine to T3 leads to increased metabolism to reverse T3 via an 862 alternate pathway. In the present study, we did not measure plasma thyroid hormone concentrations. Nevertheless, we did observe a slow onset of QT segment prolongation that reached a maximum on day 28. The temporal development of this change could be explained by the slow accumulation of amiodarone in plasma, as described earlier, or by drug-induced changes in cardiac metabolism and ionic currents. In view of the failure of short-term intravenous amiodarone to produce the same degree of QT segment prolongation on the electrocardiogram despite similar plasma and cardiac muscle concentrations and the apparent decreased efficacy of the drug with short-term administration, the occurrence of long-term metabolic adaptation appears more likely.
The role of the sympathetic nervous system in initiating ventricular fibrillation in the conscious canine preparation of sudden coronary death described pre-viously25 and used in the present study is not well understood. Acute myocardial ischemia within the distribution of the left circumflex coronary artery in the presence of previous anterior myocardial infarction produces sinus tachycardia and prolongation of the QT intervalactions suggestive of increased sympathetic nervous system activity. [25] [26] [27] It has been suggested that the electrophysiologic changes occurring in this preparation when acute myocardial ischemia is produced in the presence of previous ischemic injury are a result of activation of cardiocardiac sympathetic reflexes.26 Both ,3-adrenergic-receptor blockade27 and left stellate ganglionectomy26 prevent QT segment prolongation and suppress sinus tachycardia accompanying acute ischemia. These treatments also reduce the incidence of ventricular fibrillation. Amiodarone suppressed the development of sinus tachycardia and the prolongation LABORATORY INVESTIGATION-ARRHYTHMIA of QT segment intervals accompanying acute myocardial ischemia, suggesting possible antagonism of the actions of the sympathetic nervous system. We are unable to demonstrate an exact mechanism for the suppression of QT segment prolongation by amiodarone because several mechanisms are possible. QT segment prolongation could be suppressed by antagonism of sympathetic nervous system actions, which can result in inhomogeneous stimulation of cardiac tissue. However, by preventing the sinus tachycardia accompanying acute myocardial ischemia, amiodarone may also prevent QT segment prolongation occurring through heart rate correction errors in Bazett's formula. Unpublished observations in our own laboratory have shown that QT segment prolongation accompanying acute myocardial ischemia in the presence of previous anterior infarction can be prevented by ,B-adrenergicreceptor blockade with nadolol. This suppression can be reversed by atrial pacing at predrug sinus rates, suggesting a significant effect of heart rate in the prolongation of the QT interval. Although amiodarone inhibits the actions of catecholamines in the heart, the action is not mediated via competitive blockade of ,3adrenergic receptors and probably occurs via a postreceptor action.'I*3 The antagonism of the actions of catecholamines could, in part, explain the efficacy of both short-term intravenous and long-term oral amiodarone in our conscious canine preparation.
We are also aware of the possible role of the thyroid hormone actions of long-term amiodarone therapy in altering the sympathetic nervous system response to acute myocardial ischemia although, in the hypothyroid rat, the response to ,3-adrenergic stimulation with isoproterenol is reduced.28 However, the response to sympathetic nerve stimulation and norepinephrine administration in the anesthetized dog is not altered by I3'l pretreatment.29 Nevertheless, a reduction in sympathetic nerve activity in response to acute myocardial ischemia in animals treated with amiodarone over the long term could explain the action of the drug. A reduction in sympathetic nervous system activity would be consistent with the thyroid actions of amiodarone.
The concentration of amiodarone in atrial tissue was greater in those animals receiving long-term oral administration despite the fact that the plasma concentration of the drug was less than in animals treated over the short term. Amiodarone has a high lipid solubility and slow rate of accumulation in adipose tissue,19
reaching higher concentrations than found in plasma. Since atrial tissue samples may contain some adipose tissue not present in right ventricular samples, the adi- pose tissue may be a source of the drug measured. With short-term treatment, adipose tissue concentrations would be much smaller and would not be a significant source of drug. A major difference was observed between dogs treated over the short and long term with respect to the plasma concentrations of desethylamiodarone, a major metabolite of amiodarone. Significant amounts of the metabolite were detected in the plasma of dogs treated over the long term (1.4 + 0.02 ug/ml), whereas it was not observed in plasma from animals receiving short-term amiodarone. The amount of desethylamiodarone in atrial and ventricular tissue also exceeded that of the parent compound. To date there is little information relative to the electrophysiologic properties of desethylamiodarone and its possible contribution to the overall antidysrhythmic effects of the parent compound. Further studies are needed to quantitate the accumulation of desethylamiodarone after long-term oral administration of the parent drug and to determine if tissue and plasma concentrations of the metabolite are of electrophysiologic significance and could in part account for the delayed onset of antidysrhythmic effects of amiodarone. Amiodarone is an effective vasodilator of the coronary and peripheral vasculature.' 3 When combined with a negative chronotropic action, these hemodynamic alterations reduce myocardial oxygen consumption.2 Studies by DeBoer et al. 4 have demonstrated the ability of amiodarone to reduce the ultimate extent of irreversible injury produced by complete occlusion of the left anterior descending coronary artery in the dog. Reduction of the extent of irreversible injury and/or reduction of myocardial oxygen consumption could play a role in preventing the development of ventricular fibrillation.
Although the mechanism for the antiarrhythmic and antifibrillatory actions of amiodarone are not well understood, further studies with amiodarone may provide more information about potential mechanisms for antiarrhythmic drug action and provide a more complete understanding of mechanisms responsible for the genesis of lethal ventricular dysrhythmias.
